流感嗜血杆菌对哌拉西林-他唑巴坦组合的敏感性：标准化试验的解释标准和质量控制限度
Susceptibility of Haemophilus influenzae to piperacillin-tazobactam combinations: interpretive criteria and quality control limits for standardized tests.
作者信息
Barry A L, Fuchs P C, Jorgensen J H, Tenover F C, Allen S D, Hardy D J, McLaughlin J C
机构信息
Clinical Microbiology Institute, Tualatin, Oregon 97062.
出版信息
J Clin Microbiol. 1993 Mar;31(3):751-3. doi: 10.1128/jcm.31.3.751-753.1993.
Abstract
In vitro studies evaluated methods for testing the susceptibility of Haemophilus influenzae to piperacillin-tazobactam combinations. Ampicillin-resistant beta-lactamase-nonproducing strains of H. influenzae may be presumed to be relatively resistant to combinations of piperacillin-tazobactam, even though they frequently appear to be susceptible by disk diffusion methods. Other ampicillin-resistant or -susceptible strains were predictably susceptible; i.e., 130 such strains gave zones of inhibition > or = 26 mm in diameter, and MICs for these strains were < or = 0.125/4.0 micrograms/ml (< or = 1.0/0.12 micrograms/ml when an 8:1 ratio was tested). A resistant category has yet to be defined. For quality control purposes, H. influenzae ATCC 49247 should give zones of inhibition 32 to 38 mm in diameter, and broth microdilution MICs should be 0.12/4.0 to 0.5/4.0 micrograms/ml.
摘要
体外研究评估了检测流感嗜血杆菌对哌拉西林 - 他唑巴坦组合敏感性的方法。对氨苄西林耐药且不产β - 内酰胺酶的流感嗜血杆菌菌株可能被认为对哌拉西林 - 他唑巴坦组合相对耐药，尽管它们通过纸片扩散法通常表现为敏感。其他对氨苄西林耐药或敏感的菌株可预测为敏感；即，130株此类菌株产生的抑菌圈直径≥26 mm，这些菌株的最低抑菌浓度（MIC）≤0.125/4.0微克/毫升（当检测8:1比例时，≤1.0/0.12微克/毫升）。尚未定义耐药类别。为进行质量控制，流感嗜血杆菌ATCC 49247应产生直径为32至38 mm的抑菌圈，肉汤微量稀释法测定的MIC应为0.12/4.0至0.5/4.0微克/毫升。
相似文献
1
Susceptibility of Haemophilus influenzae to piperacillin-tazobactam combinations: interpretive criteria and quality control limits for standardized tests.流感嗜血杆菌对哌拉西林-他唑巴坦组合的敏感性：标准化试验的解释标准和质量控制限度
J Clin Microbiol. 1993 Mar;31(3):751-3. doi: 10.1128/jcm.31.3.751-753.1993.
2
Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).优化哌拉西林与他唑巴坦（YTR 830）体外试验的研究。
Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):495-510. doi: 10.1016/0732-8893(89)90084-9.
3
Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone resistance-determining regions.哌拉西林-他唑巴坦对流感嗜血杆菌分离株的抗菌活性，包括β-内酰胺酶阴性氨苄西林耐药和β-内酰胺酶阳性阿莫西林-克拉维酸耐药分离株，以及它们喹诺酮耐药决定区的突变。
Antimicrob Agents Chemother. 2009 Oct;53(10):4225-30. doi: 10.1128/AAC.00192-09. Epub 2009 Aug 3.
4
Escherichia coli ATCC 35218 as a quality control isolate for susceptibility testing of Haemophilus influenzae with haemophilus test medium.将大肠埃希菌ATCC 35218用作流感嗜血杆菌在嗜血杆菌测试培养基上进行药敏试验的质量控制菌株。
Antimicrob Agents Chemother. 1999 Feb;43(2):283-6. doi: 10.1128/AAC.43.2.283.
5
Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.利用替卡西林-克拉维酸、头孢他啶及其他广谱抗菌药物的体外试验结果预测肠杆菌科细菌、铜绿假单胞菌及其他细菌对哌拉西林-他唑巴坦的敏感性
Diagn Microbiol Infect Dis. 1994 Nov;20(3):143-9. doi: 10.1016/0732-8893(94)90108-2.
6
Use of a predictor panel to evaluate susceptibility test methods proposed for piperacillin-tazobactam.使用预测指标组评估针对哌拉西林-他唑巴坦提出的药敏试验方法。
Antimicrob Agents Chemother. 1993 Dec;37(12):2578-83. doi: 10.1128/AAC.37.12.2578.
7
Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.哌拉西林-他唑巴坦与替卡西林-克拉维酸的体外活性比较
Antimicrob Agents Chemother. 1989 Aug;33(8):1268-74. doi: 10.1128/AAC.33.8.1268.
8
The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centres and the design of a disc test for susceptibility testing.
J Antimicrob Chemother. 1993 Jul;32(1):51-61. doi: 10.1093/jac/32.1.51.
9
Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks.使用美罗培南（10微克）、亚胺培南（10微克）和氨苄西林（2微克和10微克）药敏纸片对流感嗜血杆菌的解释标准进行重新评估。
J Clin Microbiol. 1996 Aug;34(8):1970-4. doi: 10.1128/jcm.34.8.1970-1974.1996.
10
Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria.哌拉西林单独及与他唑巴坦联合应用对产β-内酰胺酶细菌的抗菌活性。
J Formos Med Assoc. 1991 Oct;90(10):947-52.
引用本文的文献
1
Molecular epidemiology of ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae.耐氨苄西林非β-内酰胺酶产生型流感嗜血杆菌的分子流行病学
J Clin Microbiol. 1998 Dec;36(12):3629-35. doi: 10.1128/JCM.36.12.3629-3635.1998.
2
Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.哌拉西林/他唑巴坦：抗菌活性、药代动力学特性及治疗潜力综述
Drugs. 1994 Mar;47(3):506-35. doi: 10.2165/00003495-199447030-00008.
本文引用的文献
1
Susceptibilities of beta-lactamase-producing and -nonproducing ampicillin-resistant strains of Haemophilus influenzae to ceftibuten, cefaclor, cefuroxime, cefixime, cefotaxime, and amoxicillin-clavulanic acid.产β-内酰胺酶和不产β-内酰胺酶的氨苄西林耐药流感嗜血杆菌菌株对头孢布烯、头孢克洛、头孢呋辛、头孢克肟、头孢噻肟及阿莫西林-克拉维酸的敏感性。
Antimicrob Agents Chemother. 1993 Jan;37(1):14-8. doi: 10.1128/AAC.37.1.14.
2
Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study.氨苄西林、羧苄西林、美洛西林和哌拉西林纸片扩散药敏试验的质量控制限度：一项协作研究。
J Clin Microbiol. 1981 Jul;14(1):67-72. doi: 10.1128/jcm.14.1.67-72.1981.
3
Characterization of non-beta-lactamase-mediated ampicillin resistance in Haemophilus influenzae.流感嗜血杆菌中非β-内酰胺酶介导的氨苄西林耐药性的特征分析。
Antimicrob Agents Chemother. 1984 Aug;26(2):235-44. doi: 10.1128/AAC.26.2.235.
4
Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae.用于流感嗜血杆菌抗菌药敏试验的改良培养基。
J Clin Microbiol. 1987 Nov;25(11):2105-13. doi: 10.1128/jcm.25.11.2105-2113.1987.
5
Haemophilus influenzae: antibiotic susceptibility.流感嗜血杆菌：抗生素敏感性
Clin Microbiol Rev. 1988 Apr;1(2):218-27. doi: 10.1128/CMR.1.2.218.
6
Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).优化哌拉西林与他唑巴坦（YTR 830）体外试验的研究。
Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):495-510. doi: 10.1016/0732-8893(89)90084-9.
7
Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).哌拉西林与β-内酰胺酶抑制剂他唑巴坦（YTR 830）联合应用的体外比较活性
Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):481-8. doi: 10.1016/0732-8893(89)90082-5.
8
Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States.美国流感嗜血杆菌、卡他莫拉菌和肺炎链球菌呼吸道分离株中的抗菌药物耐药性
Antimicrob Agents Chemother. 1990 Nov;34(11):2075-80. doi: 10.1128/AAC.34.11.2075.
9
Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella (Branhamella) catarrhalis isolated in the UK from sputa.在英国从痰液中分离出的肺炎链球菌、流感嗜血杆菌和卡他莫拉菌（布兰汉菌）的抗菌药敏性
J Antimicrob Chemother. 1991 Aug;28(2):249-59. doi: 10.1093/jac/28.2.249.
10
Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam.
Eur J Clin Microbiol Infect Dis. 1992 Aug;11(8):728-32. doi: 10.1007/BF01989979.
Zotero 插件